ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Summarizing multiple studies worldwide, mutations in the ABL kinase domain accounts for about 22.4%-54.46% of resistance CML patients, with p-loop mutations accounting for about one-fourth6, 7.